Unither Pharmaceuticals in the news

Unither Pharmaceuticals is investing 140 million euros in a new 20,000 m² sterile production facility in Gannat, France, partnering with Théa to boost ophthalmic treatment manufacturing and create 250 jobs.

Théa and Unither Pharmaceuticals are investing 140 million euros in a new 20,000 m" factory in Gannat, Allier, as part of an industrial partnership.

Théa and Unither Pharmaceuticals are partnering to build a dedicated —140 million ophthalmic production unit in France, expected to produce 50 million treatments annually by 2029.

Théa Group and Unither Pharmaceuticals are investing over —140 million to build a dedicated ophthalmic manufacturing facility in France, set to be operational by 2028.

Théa and Unither Pharmaceuticals announced a strategic industrial partnership for a new ophthalmic production unit in Auvergne, France, dedicated to manufacturing Théa's sterile products.

Théa and Unither Pharmaceuticals are partnering to build a 140 million euro ophthalmic manufacturing facility in France.

A new educational web series called Eye to Market features industry experts discussing the development and manufacturing of ophthalmic innovations.

Expansion at the Gannat site will double the workforce by 2029 and introduce new eye drop production lines supported by a new local apprenticeship program.

Unither Pharmaceuticals appointed Henrik Krüpper as the new CEO, succeeding Eric Goupil, as the company continues its growth, innovation focus, and industrial expansion with a new facility in France.

Unither Pharmaceuticals appointed Henrik Krüpper as CEO to lead its global strategy, operational expansion, and innovation in sterile unit-dose contract manufacturing.

Eyecelerator, Unither Pharmaceuticals, and Ora launched "Eye to Market," a web series to demystify ophthalmic innovation pathways for professionals.

Eyecelerator, Unither Pharmaceuticals, and Ora, Inc. launched a web series to clarify the ophthalmic innovation pathway for industry professionals.

Eyecelerator, Unither Pharmaceuticals, and Ora launched a web series, "Eye to Market," to explore how ophthalmic innovations transition from scientific insight to market adoption.

Théa and Unither Pharmaceuticals established a strategic partnership for a new dedicated ophthalmic manufacturing facility in France to support Théa's European growth.

The French Blow Fill Seal technology market is expanding due to strong demand for biologics and injectable therapies, with key players investing in advanced sterile packaging solutions.

Unither Pharmaceuticals employs 1,506 people and leads the global market in sterile unit-dose contract manufacturing across eight international plants.

Unither Pharmaceuticals, a sterile unit-dose manufacturer, acquired Austrian company Carragelose in late 2024.

Unither Pharmaceuticals, founded in 1993, specializes in sterile unit-doses and effervescent tablets, expanding internationally and was recently acquired by a management-led consortium.

Unither Pharmaceuticals is investing €140 million to expand its sterile unit-dose production in Gannat, aiming to nearly double output by 2029 and create significant local jobs.

Unither Pharmaceuticals is investing 140 million euros and creating 250 jobs to build a new sterile ophthalmic production facility in Gannat.